EU Pharma Ups Share Buybacks In 2012
This article was originally published in The Pink Sheet Daily
Executive Summary
Share buybacks are controversial in the biopharma industry, but European pharma companies, facing tough operating environments and pressures on near-term financials, are planning to invest in them in 2012 more than in recent years.
You may also be interested in...
GSK's Lost Quarter: $3 Billion DoJ Settlement Far Outstrips Net Profit
If approved, the settlement would set a new record for the pharmaceutical industry in its dealings with the federal government, but would be covered by the firm's existing reserves.
Pharma, Uncertain Of What To Do With Its Cash, Turns To Share Buybacks
Pfizer Inc.'s announcement on Feb. 1 that it plans an enormous, near-term share repurchasing program caught investors' attention and highlighted a persistent, if sometimes muted, ongoing debate in the industry about the best use of its cash.
AstraZeneca Hit By U.S. Generic Competition In 2010; Extends Share Buyback Program
Revenues flat year on year, but profits up 5% in a year of cost savings and late-stage product disappointments.